Camrelizumab plus chemotherapy in advanced non‐squamous non‐small cell lung cancer: Treatment response, survival pattern, and safety-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Camrelizumab plus chemotherapy in advanced non‐squamous non‐small cell lung cancer: Treatment response, survival pattern, and safety

Published:2022-07-18 Issue:11 Volume:47 Page:1775-1782
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:Clinical Pharmacy Therapeu

Author:

Cao Hui¹,Wei Wei¹,Lu Yang¹^ORCID

Affiliation:

1. Department of Pulmonary and Critical Care Medicine The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13732

Reference35 articles.

1. Lung Cancer

2. Lung Cancer 2020

3. Current Cancer Epidemiology

4. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports;Frontiers in Oncology;2023-08-03

2. Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review;iLIVER;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP